Literature DB >> 9815945

p53 antibodies in patients with various types of cancer: assay, identification, and characterization.

R Lubin1, B Schlichtholz, J L Teillaud, E Garay, A Bussel, C P Wild.   

Abstract

Alteration of the p53 gene is the most frequent genetic alteration in human cancer and leads to the accumulation of mutant p53 in the nucleus of tumor cells. In addition, it has been shown that patients with various types of neoplasia have p53 antibodies in their sera which could be used as an indirect diagnostic procedure for p53 alteration. Using a new ELISA, we have analyzed the sera from more than 1000 patients with various types of cancer and from healthy blood donors. We demonstrate that p53 antibodies are detected mainly in cancer patients and are strictly proportional to the occurrence of p53 mutations. Using various immunological approaches, these antibodies were unambiguously demonstrated to be directed toward the human p53 protein. Isotyping analysis of these antibodies strongly suggested that they correspond to a humoral response to the p53 protein which accumulates in the tumor cell. This finding suggests that serological analysis, combined with histochemistry, is suitable for assessing the integrity of the p53 gene in cancer patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9815945

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  34 in total

1.  Detection and monitoring of serum p53 antibodies in patients with colorectal cancer.

Authors:  P Hammel; B Boissier; M T Chaumette; P Piedbois; N Rotman; J C Kouyoumdjian; R Lubin; J C Delchier; T Soussi
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

2.  Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients.

Authors:  Keiji Shimizu; Yuji Ueda; Hisakazu Yamagishi
Journal:  Gastric Cancer       Date:  2005       Impact factor: 7.370

Review 3.  A systematic review of humoral immune responses against tumor antigens.

Authors:  Miriam Reuschenbach; Magnus von Knebel Doeberitz; Nicolas Wentzensen
Journal:  Cancer Immunol Immunother       Date:  2009-06-28       Impact factor: 6.968

4.  Humoral immune response to p53 in malignant glioma.

Authors:  M Weller; A Bornemann; M Ständer; M Schabet; J Dichgans; R Meyermann
Journal:  J Neurol       Date:  1998-03       Impact factor: 4.849

5.  Osteopontin is a tumor autoantigen in prostate cancer patients.

Authors:  Tatiana M Tilli; Eloísio A Silva; Lívia C Matos; Douglas V Faget; Bianca F P Dias; Juliana S P Vasconcelos; Yasuyuki Yokosaki; Etel R P Gimba
Journal:  Oncol Lett       Date:  2010-11-23       Impact factor: 2.967

6.  Rapid and Sensitive Detection of p53 Based on DNA-Protein Binding Interactions Using Silver Nanoparticle Films and Microwave Heating.

Authors:  Muzaffer Mohammed; Kadir Aslan
Journal:  Nano Biomed Eng       Date:  2014-11-10

Review 7.  Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies.

Authors:  M Abu-Shakra; D Buskila; M Ehrenfeld; K Conrad; Y Shoenfeld
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

8.  Secreted recombinant P53 protein from Pichia pastoris is a useful antigen for detection of serum p53: autoantibody in patients with advanced colorectal adenocarcinoma.

Authors:  Salma Abdelmoula-Souissi; Nourane Zouari; Imen Miladi-Abdenadher; Ouhoud Yaich-Kolsi; Ines Ayadi-Masmoudi; Abdelmajid Khabir; Hatem Masmoudi; Mounir Frikha; Raja Mokdad-Gargouri
Journal:  Mol Biol Rep       Date:  2013-03-26       Impact factor: 2.316

9.  Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients.

Authors:  A Kulić; M Sirotković-Skerlev; S Jelisavac-Cosić; D Herceg; Z Kovac; D Vrbanec
Journal:  Med Oncol       Date:  2009-09-11       Impact factor: 3.064

10.  Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy.

Authors:  Mirna Lechpammer; Josip Lukac; Stanislav Lechpammer; Dujo Kovacević; Massimo Loda; Zvonko Kusić
Journal:  Int J Colorectal Dis       Date:  2003-11-21       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.